Tag Archives: Acquisition

December, 2018

27 December
Boston Scientific Acquires Remaining Shares of Millipede, Expanding its Heart Portfolio

MARLBOROUGH, Mass., Dec. 27, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Millipede, Inc, a privately-held company in Santa Rosa, Calif., upon its recent successful completion of a first-in-human clinical study. The acquisition will expand the Boston Scientific …
Share

25 October
AbbVie Assumes Full Development and Commercial Control of Galapagos’ Cystic Fibrosis Assets

NORTH CHICAGO, Ill., Oct. 24, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that it will assume full development and commercial responsibility for its collaboration with Galapagos (Euronext: GLPG) to discover and develop new therapies to treat cystic fibrosis (CF). AbbVie’s research program aims to develop a …
Share
24 October
AstraZeneca Strengthens and Expands Oncology Development and Commercialization Collaboration with Innate Pharma

AstraZeneca, and its global biologics research and development arm MedImmune, today announced a new multi-term agreement with Innate Pharma (Innate), building on an existing collaboration, aimed at accelerating each company’s oncology portfolio and bringing new medicines to patients more quickly. The extended collaboration will enrich AstraZeneca’s immuno-oncology (IO) portfolio with …
Share

25 April
Shire Announces Further Revised Proposal from Takeda Regarding the Potential $64 Billion Takeover Bid

The Board of Shire (the “Board”) announced earlier today that it had received a further revised proposal from Takeda Pharmaceutical Company Limited (“Takeda”) regarding a possible offer for the Company. The revised proposal comprises 0.839 new Takeda shares and US$30.33 in cash for each Shire ordinary share (the “Revised Proposal”). …
Share
5 April
Agilent Technologies to Acquire Lasergen for $105 Million

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) and Lasergen, Inc. (Lasergen) today announced that they have signed a definitive agreement for Agilent to acquire the remaining shares of Lasergen, an emerging biotechnology company focused on research and development of innovative technologies for DNA sequencing, for $105 million. In March 2016 …
Share

27 October
Evotec and Tesaro Partner to Discover Novel Immuno-Oncology Agents

HAMBURG, Germany–(BUSINESS WIRE)–Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and TESARO, Inc. (“TESARO”) today announced a three-year integrated drug discovery collaboration to discover and develop novel small molecule product candidates against an undisclosed immuno-oncology (IO) target. Under the terms of the collaboration, Evotec will apply its integrated drug …
Share

17 May
Thermo Fisher to Acquire Leading CDMO Patheon for $7.2 Billion

WALTHAM, Mass. and DURHAM, N.C., May 15, 2017 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of …
Share

18 April
Cardinal Health Buys Three Units from Medtronic for $6.1 Billion

DUBLIN, Ohio, April 18, 2017 /PRNewswire/ — Cardinal Health (NYSE: CAH) today announced that it has entered into a definitive agreement to acquire Medtronic’s Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses for $6.1 billion in cash. The purchase price does not include cash tax benefits of at least $100 …
Share

5 March
Novartis Sells its RNAi Assets to Arrowhead Research

Today, Arrowhead Research Corporation announced that it has acquired Novartis’ entire RNAi business for $10 million in cash and $25 million in stock. The deal gives Arrowhead Novartis’ complete RNAi research and development portfolio and associated assets, including assignment of certain Novartis patents and patent applications related to RNAi therapeutics, …
Share
2 March
Cardinal Health to Buy Johnson & Johnson’s Cordis for Nearly $2 Billion

Johnson & Johnson announced that it is selling its Cordis business, which makes vascular technology, to Cardinal Health for approximately $1.94 billion. Cardinal will acquire Cordis for an aggregate value of $1.99 billion, consisting of $1.944 billion of cash proceeds plus approximately $46 million of retained net receivables. Cordis is …
Share